| Document |
Document Title |
|
WO/2022/104148A1 |
Disclosed herein, inter alia, are compounds for inhibiting IREl α and uses thereof.
|
|
WO/2022/089774A1 |
The invention relates to a process for preparing 1,2'-benzisothiazoline-3-one according to formula (I), comprising the following steps: (a) reacting a 2-halogenbenzonitrile compound of general formula (II) with a reaction mixture, contai...
|
|
WO/2022/078533A1 |
The present invention relates to substituted 1-phenyl-3-yl-urea derivatives of the general formula (I), and preparations containing these derivatives, (I) wherein Y is nitrogen or carbon; R1 is halogen, methoxy group, methylsulfanyl grou...
|
|
WO/2015/136292A9 |
The invention relates to a DDX3X inhibitorfor use in the treatment of pneumovirus infection in a mammal, wherein the DDX3X inhibitor may be a compound of Formula (I) wherein y, Z, R1, X, L, Ra and Rb are as defined herein. The invention ...
|
|
WO/2022/048922A1 |
The present invention relates to a compound of the following formula (I) or (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture the...
|
|
WO/2022/034201A1 |
Bisorthohydroxy aromatic urones and their use as curatives and cure accelerators in resin systems particularly epoxy resin systems provide formulations with good outlife, low curing temperatures and desirable glass transition temperature...
|
|
WO/2022/027122A1 |
The present invention is related to compositions containing only natural products for the treatment of erectile and sexual dysfunction (ESD). More specifically relates to compositions containing Cannabis extract, and other herbal extract...
|
|
WO/2022/018450A1 |
The present invention relates to crystalline forms of vadadustat, including a crystalline vadadustat anhydrate and a crystalline vadadustat urea molecular complex. The present invention also relates to processes for their preparation and...
|
|
WO/2022/003181A1 |
The present invention relates to urea derivatives of polyene macrolides having the following chemical formula: wherein: - R1 is hydrogen or an alkyl or aryl or acyl group, and R2, independently of R1, is hydrogen or an alkyl or aryl or a...
|
|
WO/2021/260090A1 |
The invention relates to compounds of Formula (I) wherein X1, X2, X3, L, RX4, R1, R2A, R2B, R3, R4, R5, and R6 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical com...
|
|
WO/2021/257669A1 |
The present disclosure includes synthetic methods for preparing certain substituted (hetero)arylmethyl urea compounds, compositions comprising the same, and crystalline forms thereof, which can be used to treat, ameliorate, and/or preven...
|
|
WO/2021/252640A1 |
The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, interme...
|
|
WO/2021/246485A1 |
Provided is a carbamate production method characterized by bringing a carbon dioxide-containing mixed gas in which the partial pressure of carbon dioxide is 0.001 atm or greater but less than 1 atm, into contact with an amino group-conta...
|
|
WO/2021/246316A1 |
The present invention reduces energy derived CO2 through effective use of CO2 that is in exhaust gas from a cement production facility and that is not derived from fossil fuel, by converting CO2 in exhaust gas from a cement production fa...
|
|
WO/2021/230956A1 |
The present disclosure provides processes and apparatuses for the scaled-up manufacture of lomustine via continuous flow manufacture. Such continuous flow processes may optionally include the crystallization of lomustine and the apparatu...
|
|
WO/2021/226276A2 |
Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a ph...
|
|
WO/2021/219594A1 |
The invention relates to compounds of Formula (I) wherein X1, X2, X3, Y, R1, R2A, R2B, R3, and R4 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical compositions con...
|
|
WO/2021/222789A1 |
Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.
|
|
WO/2021/214048A1 |
The invention pertains to a novel structure (I) that provides an activity as a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and 5-lipoxygenase (5-LOX). The invention pertains to multiple derivatives of the new class of d...
|
|
WO/2021/217041A1 |
Disclosed are N-substituted α-amino and α-hydroxy carboxamides, pharmaceutical compositions comprising them, and methods of using them.
|
|
WO/2021/217040A1 |
Disclosed are carbamate and urea derivatives, pharmaceutical compositions comprising them, and methods of using them.
|
|
WO/2021/211436A1 |
The present application provides idebenone derivatives or analogues useful for treating a disease or disorder in a subject in need thereof. Pharmaceutical compositions comprising the compounds and methods of treating the disease or disor...
|
|
WO/2021/206132A1 |
Provided is a method for producing, using a simple procedure, an O-methylisourea sulfate that is important as an intermediate of medicines, agrochemicals and industrial chemicals. The present invention is a method for producing an O-me...
|
|
WO/2021/204175A1 |
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid...
|
|
WO/2021/185391A1 |
The present invention relates to substituted 1-[2-(hydroxyalkyl)phenyl]-3-yl-urea derivatives of the general formula (I), which inhibit one of the key plant enzymes cytokinin oxidase/dehydrogenase (CKX); wherein R1 is hydrogen, halogen, ...
|
|
WO/2021/185390A1 |
The present invention relates to substituted 2-(3-phenylureido)benzamide derivatives of the general formula (I), wherein R1 is hydrogen, amino group, (C1 to C5)alkyl, (C2 to C5)alkenyl or (C2 to C5)alkynyl, optionally substituted with hy...
|
|
WO/2021/180655A1 |
The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and/or preventing e.g. autoimmune, immunological, rheumatology, vascul...
|
|
WO/2021/182457A1 |
[Problem] To develop novel compounds having an activity of inhibiting the function of Pin1 so as to use these compounds as pharmaceutical candidate compounds. [Solution] A compound represented by formula (I) or a salt thereof, and a Pin1...
|
|
WO/2021/170154A1 |
Method of purification of carglumic acid, substance formula I, contains the following steps: a) Dissolution of carglumic acid in dimethyl sulfoxide; b) Addition of a precipitation solvent; c) Isolation of the precipitated solvate of carg...
|
|
WO/2021/168561A1 |
The present invention provides solvent-limited processes for the preparation of an existing crystalline solid form of an active pharmaceutical ingredient comprising mixing, in the presence of solvent vapour, of a solid active pharmaceuti...
|
|
WO/2021/159015A1 |
Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formul...
|
|
WO/2021/142570A1 |
The present invention provides a method for preparing storage-stable biuret polyisocyanate. The biuret polyisocyanate product obtained by using the method of the present invention has excellent monomer content storage stability, i.e. lit...
|
|
WO/2021/119108A1 |
The present invention describes methods for treating idiopathic short stature. Described herein are also methods of increasing a subject's height. The methods involve administering an effective amount of a pan FGFR inhibitor or a selecti...
|
|
WO/2021/098671A1 |
Disclosed is an ureido-containing benzimidazole derivative, wherein the general structural formula is as shown in formula (I). Also disclosed are a method for preparing the compound and the use thereof in the preparation of anti-chronic ...
|
|
WO/2021/102266A1 |
Di alkenyl succinic amide acids and processes for making and using same. The di alkenyl succinic amide acid can have a chemical formula of (I): where R1 and R2 can independently be a linear or branched C8 to C24 alkenyl group, Z1, Z2, Z3...
|
|
WO/2021/080352A1 |
The present invention relates to: a derivative in which glutamate-urea-Lysine (GUL) and isonitril are linked by a linker; a radioisotope labeled compound comprising the derivative; and a pharmaceutical composition for treating and diagno...
|
|
WO/2021/056665A1 |
Disclosed in the present invention are a gemini surfactant for oil displacement, and a preparation method for and an application of the gemini surfactant. The gemini surfactant is 1,3-dialkyl-1,3-dipolyoxyethylene ether urea or 1,3-dialk...
|
|
WO/2021/038490A1 |
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3 ...
|
|
WO/2021/027237A1 |
The present invention relates to a method for preparing a supercritical carbon dioxide thickener for the exploitation of tight oil and gas reservoirs. The method can solve the problem of oil and gas deposits being damaged as a result of ...
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2021/008908A1 |
The invention relates to a method for producing polyisocyanates having a low monomer content, said method comprising the following steps: (i) modifying at least one monomeric diisocyanate to obtain a mixture containing at least one polyi...
|
|
WO/2020/264176A1 |
Heteroaryl and aliphatic analogs of diarylurea-based cannabinoid 1 receptor (CB1 R) allosteric modulators of formula (I) are described. Exemplary analogs can provide improved potencies and pharmacokinetic properties. Methods of using the...
|
|
WO/2020/252240A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/210909A1 |
This application relates to compounds of Formula I. R1a, R1b and R1c is –CO2H, –SO2H, –SO3H, –SO4H, –PO2H, –PO3H or –PO4H. R2 is a linker, e.g. butylene. R3 is a linkage, e.g.–O–, –S–, -S(O)-, S(O)2-, –NHC(O)–, ...
|
|
WO/2020/196553A1 |
The purpose of the present invention is to provide a method that enables efficient and safe production of an N-substituted trihaloacetamide which also serves as a synthetic intermediate for isocyanate compounds, carbamate compounds, urea...
|
|
WO/2020/183745A1 |
Provided are a new urea production method and device that enable heat recovery from a fluid at a relatively low temperature. This urea production method includes a synthesis step, a high-pressure decomposition step, and a condensation st...
|
|
WO/2020/156345A1 |
The present invention relates to the technical field of biomedicine, and specifically relates to a PSMA inhibitor, a compound and an application. The PSMA inhibitor having a novel core structure as provided by the present invention has v...
|
|
WO/2020/150740A1 |
Prostate-specific membrane antigen (PSMA) targeted compounds having formula (I), nanoclusters formed thereof, pharmaceutical compositions comprising a plurality of these compounds, and methods for treating and detecting cancers in a subj...
|
|
WO/2020/148760A1 |
The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.
|
|
WO/2020/139012A1 |
The present invention relates to a 18F-labeled compound for diagnosing prostate cancer and a use thereof. The carboxylic acid-introduced compound of the present invention forms strong ion-pair bonds (salt-bridge interactions) with argini...
|
